Download the poster and explore the discovery of highly specific anti-WT1/HLA-A2 TCR-like antibodies.
In a significant study, Alloy Therapeutics researchers identified T Cell Receptor mimic (TCRm) antibodies with exceptional specificity for the Wilms Tumor 1 (WT1) antigen, ranked by National Cancer Institute as number one of the top targets for cancer immunotherapy. Identifying binders to WT-1/HLA-A2 is particularly challenging due to high homology with other peptides (M13L and PIGQ).
The Keyway TCRm Antibody Discovery Platform, powered by ATX-Gx™ transgenic mice, enabled the generation of highly specific antibodies with superior affinity and specificity compared to the three commercially available benchmark antibodies. This breakthrough has the potential to transform cancer treatment by enabling the development of TCRm-based therapies with enhanced efficacy and reduced off-target effects
Complete this form to download and view the poster
Our TCRm antibodies demonstrate superior target specificity, minimizing off-target effects and improving safety profiles
Our TCRm antibodies demonstrate superior target specificity, minimizing off-target effects and improving safety profiles
This technology can be applied to various targets and diseases, expanding the potential of TCRm-based therapies beyond hematological cancers
TCRm antibodies are adaptable to diverse formats, including bispecific antibodies and engineered cell therapies
